2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.100 Daniel Principe Abstract

PP01.100 Daniel Principe Abstract

Pdf Summary

A study conducted by researchers at the University of Illinois College of Medicine in Chicago highlights the association between co-mutation of the KRAS and TP53 genes and increased tumor immunogenicity in non-small cell lung cancer (NSCLC) patients. The researchers enrolled 189 NSCLC patients, the majority of whom were from racial and ethnic minority backgrounds, and analyzed their tumor specimens using various techniques such as immunohistochemistry, DNA sequencing, and RNA sequencing. They found that patients with activating KRAS mutations showed a significant increase in PD-L1 expression, regardless of TP53 mutation status. Additionally, KRAS-mutated patients had a higher infiltration of CD8 T-cells, a type of immune cell associated with anti-tumor immune responses. The study also found that KRAS mutation was associated with improved overall survival in these patients who were receiving or had received immune checkpoint inhibitors (ICIs) as part of their treatment. While the combined KRAS/TP53 co-mutation also showed a trend towards improved survival, it did not reach statistical significance due to the smaller sample size. The researchers suggest that the co-mutation of KRAS and TP53 genes may serve as a potential predictive biomarker for response to ICIs. These findings emphasize the need for clinically useful biomarkers to better stratify NSCLC patients for ICI-based immunotherapy and further exploration of co-mutations as potential predictive biomarkers.

Keywords

co-mutation

KRAS gene

TP53 gene

tumor immunogenicity

non-small cell lung cancer

PD-L1 expression

CD8 T-cells

immune checkpoint inhibitors

predictive biomarker

immunotherapy